LEXICON PHARMACEUTICALS, INC. Other Noncash Income (Expense)
LEXICON PHARMACEUTICALS, INC. (LXRX) reported Other Noncash Income (Expense) of $99.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OtherNoncashIncomeExpense · last filed 2026-08-06
- LEXICON PHARMACEUTICALS, INC. other noncash income (expense) for the quarter ending 2026-06-30 was -$482.00K, a 2395.24% decline year-over-year.
- LEXICON PHARMACEUTICALS, INC. other noncash income (expense) for the quarter ending 2026-03-31 was $581.00K, a 62.27% decline year-over-year.
- LEXICON PHARMACEUTICALS, INC. other noncash income (expense) for the quarter ending 2025-12-31 was $163.00K.
- LEXICON PHARMACEUTICALS, INC. other noncash income (expense) for the quarter ending 2025-09-30 was $18.00K.
- LEXICON PHARMACEUTICALS, INC. other noncash income (expense) for fiscal 2025 was $1.74M.
- LEXICON PHARMACEUTICALS, INC. other noncash income (expense) for fiscal 2024 was -$812.00K.
- LEXICON PHARMACEUTICALS, INC. other noncash income (expense) for fiscal 2023 was -$1.51M.
- LEXICON PHARMACEUTICALS, INC. other noncash income (expense) for fiscal 2022 was $0.00.
| Period end | Other Noncash Income (Expense) 3 month | Other Noncash Income (Expense) 3 month as first filed | Other Noncash Income (Expense) 6 month | Other Noncash Income (Expense) 6 month as first filed | Other Noncash Income (Expense) 9 month | Other Noncash Income (Expense) 9 month as first filed | Other Noncash Income (Expense) 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$482.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $99.00K 10-Q · filed 2026-08-06 | $262.00K derived: sum of 3 quarters · filed 2026-08-06 | $280.00K derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2026-03-31 | $581.00K 10-Q · filed 2026-05-07 | $744.00K derived: sum of 2 quarters · filed 2026-05-07 | $762.00K derived: sum of 3 quarters · filed 2026-05-07 | $783.00K derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-12-31 | $163.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $181.00K derived: sum of 2 quarters · filed 2026-03-05 | $202.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.74M 10-K · filed 2026-03-05 | |||
| 2025-09-30 | $18.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $39.00K derived: sum of 2 quarters · filed 2026-08-06 | $1.58M 10-Q · filed 2025-11-06 | $1.25M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-06-30 | $21.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.56M 10-Q · filed 2026-08-06 | $1.23M derived: sum of 3 quarters · filed 2026-08-06 | $352.00K derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-03-31 | $1.54M 10-Q · filed 2026-05-07 | $1.21M derived: sum of 2 quarters · filed 2026-05-07 | $331.00K derived: sum of 3 quarters · filed 2026-05-07 | $1.90M derived: sum of 4 quarters · filed 2026-05-07 | |||
| 2024-12-31 | -$331.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$1.21M derived: sum of 2 quarters · filed 2026-03-05 | $361.00K derived: sum of 3 quarters · filed 2026-03-05 | -$812.00K 10-K · filed 2026-03-05 | |||
| 2024-09-30 | -$878.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $692.00K derived: sum of 2 quarters · filed 2025-11-06 | -$481.00K 10-Q · filed 2025-11-06 | -$1.99M derived: sum of 4 quarters · filed 2026-03-05 | |||
| 2024-06-30 | $1.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $397.00K 10-Q · filed 2025-08-06 | $5.11M 10-Q · filed 2024-08-02 | -$1.11M derived: sum of 3 quarters · filed 2026-03-05 | -$1.11M derived: sum of 4 quarters · filed 2026-03-05 | ||
| 2024-03-31 | -$1.17M 10-Q · filed 2025-05-14 | $226.00K 10-Q · filed 2024-05-02 | -$2.69M derived: sum of 2 quarters · filed 2026-03-05 | -$2.69M derived: sum of 3 quarters · filed 2026-03-05 | -$2.69M derived: sum of 4 quarters · filed 2026-03-05 | ||
| 2023-12-31 | -$1.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$1.51M derived: sum of 2 quarters · filed 2026-03-05 | -$1.51M derived: sum of 3 quarters · filed 2026-03-05 | -$1.51M 10-K · filed 2026-03-05 | |||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $0.00 derived: sum of 2 quarters · filed 2024-11-13 | $0.00 10-Q · filed 2024-11-13 | $3.61M 10-Q · filed 2023-11-08 | $0.00 derived: sum of 4 quarters · filed 2025-03-07 | ||
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-02 | $0.00 10-Q · filed 2024-08-02 | $0.00 derived: sum of 3 quarters · filed 2025-03-07 | ||||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-02 | $0.00 derived: sum of 2 quarters · filed 2025-03-07 | |||||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $0.00 10-K · filed 2025-03-07 | |||||
| 2022-09-30 | $0.00 10-Q · filed 2023-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |